专利号:US-12383499-B2 优先权日:2018-01-01 标题:Scale up synthesis of silicasome nanocarriers 发明人:NEL ANDRE E; MENG HUAN; LIU XIANGSHENG 权利人:UNIV CALIFORNIA 摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).
专利号:US-12351573-B2 优先权日:2019-05-09 标 题:Compounds for use in synthesis of peptidomimetics 发明人:AL-ABED YOUSEF; CHENG KAI FAN 权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 摘要:Synthesis of O-benzotriazole and O-imidazole synthons are described. Uses of synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the synthons and uses of azapeptides and other peptidomimetics are also described.
专利号:US-2023159450-A1 优先权日:2020-05-08 标 题 :Dimers for use in synthesis of peptidomimetics 发明人:AL-ABED YOUSEF; ALTITI AHMAD 权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 摘要:Dimers for use in synthesis of peptidomimetics are described. Uses of dimers as synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the dimers and uses of azapeptides and other peptidomimetics are also described.
专利号:US-12391691-B2 优先权日:2018-11-16 标题:Synthesis of key intermediate of KRAS G12C inhibitor compound 发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY 权利人:AMGEN INC 摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as
专利号:US-2025206736-A1 优先权日:2019-11-14 标题 :Synthesis of kras g12c inhibitor compound 发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN 权利人:AMGEN INC 摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
专利号:US-2020354404-A1 优先权日:2019-05-09 标 题 :Peptidomimetic agents, synthesis and uses thereof 发明人:AL-ABED YOUSEF 权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 摘要:Compounds for use in synthesis of peptidomimetic agents; synthesis of peptidomimetic agents; peptidomimetic diagnostic and therapeutic agents; and uses of the compounds and peptidomimetic agents in drug discovery, diagnosis, prevention and treatment of diseases are described.
1: Kang HE, Seo Y, Kim Y, Kim J. Combined treatment of TKIs with Cilengitide overcomes afatinib-resistance in EGFR-mutated NSCLC cells. Mol Biol Rep. 2025 Dec 29;53(1):233. doi: 10.1007/s11033-025-11405-2. 54(7):597-606. doi: 10.1111/jop.70004. Epub 2025 Jul 1. 26(1):187. doi: 10.1186/s13058-024-01942-2. 4: Guo DY, Chen ZH, Fu YF, Li YY, Chen MN, Wu JJ, Yuan ZD, Ye JX, Li X, Yuan FL. Corrigendum to "Cilengitide inhibits osteoclast adhesion through blocking the αvβ3-mediated FAK/Src signaling pathway" [Heliyon 9(7) (July 2023) e17841]. Heliyon. 2023 Nov 24;10(1):e22629. doi: 10.1016/j.heliyon.2023.e22629. Erratum for: Heliyon. 2023 Jun 29;9(7):e17841. doi: 10.1016/j.heliyon.2023.e17841. 5: Flies CM, Friedrich M, Lohmann P, van Garderen KA, Smits M, Tonn JC, Weller M, Galldiks N, Snijders TJ. Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide. Neuro Oncol. 2024 May 3;26(5):902-910. doi: 10.1093/neuonc/noad247.
合成参考文献
参考文献:10.1007/s00259-002-0783-8 摘要:Van de Wiele C, Oltenfreiter R, De Winter O, Signore A, Slegers G, Dierckx R. Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2002 Mar 22;29(5):699–709. doi: 10.1007/s00259-002-0783-8. 参考文献:10.3892/or.19.4.1039 摘要:Tentori L, Dorio A, Muzi A, Lacal P, Ruffini F, Navarra P, Graziani G. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep. 2008 Apr 01;(). doi: 10.3892/or.19.4.1039. 参考文献:10.1186/bcr2835 摘要:Clézardin P. Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res. 2011 Apr 06;13(2):207. 参考文献:10.4137/cmo.s7232 摘要:Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol. 2011;5():117–29. 参考文献:10.4414/smw.2011.13210 摘要:Weller M. Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Med Wkly. 2011;141():w13210. doi: 10.4414/smw.2011.13210.